Haloprogin: a topical antifungal agent.
Haloprogin was shown to be a highly effective agent for the treatment of experimentally induced topical mycotic infections in guinea pigs. Its in vitro spectrum of activity also includes yeasts, yeastlike fungi (Candida species), and certain gram-positive bacteria. The in vitro and in vivo antifungal activity of haloprogin against dermatophytes was equal to that observed with tolnaftate. The striking differences between the two agents were the marked antimonilial and selective antibacterial activities shown by haloprogin, contrasted with the negligible activities found with tolnaftate. Addition of serum decreased the in vitro antifungal activity of haloprogin to a greater extent than that of tolnaftate; however, diminished antifungal activity was not observed when haloprogin was applied topically to experimental dermatophytic infections. Based on its broad spectrum of antimicrobial activity, haloprogin may prove to be a superior topical agent in the treatment of dermatophytic and monilial infections in man.
D000818:Animals; D000935:Antifungal Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001419:Bacteria / Q000187:drug effects; D055598:Chemical Phenomena; D002621:Chemistry; D003881:Dermatomycoses / Q000188:drug therapy; D004195:Disease Models, Animal; D004987:Ethers / Q000627:therapeutic use*; D005658:Fungi / Q000187:drug effects; D006168:Guinea Pigs; D008297:Male; D014005:Tinea / Q000188:drug therapy*; D014249:Trichophyton; D015003:Yeasts / Q000187:drug effects
D000935:Antifungal Agents; D004987:Ethers